This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences Update: Second Quarter 2013

Deloitte Corporate Finance LLC


This quarter’s Life Sciences Update, produced by Deloitte Corporate Finance LLC (DCF), summarizes recent transactions within this industry along with information on active buyers, current transaction valuation multiples and an overview of the public market’s perception of the industry.

Highlights include:

  • Life science companies continue to approach product/company acquisitions, early stage investments and IPOs cautiously amid continued uncertainty regarding healthcare reform and potential regulatory changes.
  • Medical device companies continue the push to expand into global markets to counteract regulatory and pricing pressures in the U.S. as well as decreased demand for certain therapeutic areas.
  • Advances in biotechnology are continuing to drive the trend of outsourcing R&D responsibilities to external firms with more specialized expertise.
  • Access to capital, which has been an issue for small players in the industry, will increase as large pharmaceutical players continue their M&A strategy in the biotechnology industry.

To learn more, download the Life Sciences Update.


Stay Connected